Investor relations
With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.
We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.
Press Releases
Sedana Medical secures data exclusivity and market protection for Sedaconda[®] (isoflurane) until 2031
Non-regulatory
Sedana Medical AB (publ) announces that the European Medicines Agency’s Paediatric Committee has iss…
Key results of Sedana Medical’s paediatric study IsoCOMFORT published
Non-regulatory
Sedana Medical AB (publ) today announces that the main results from the paediatric IsoCOMFORT study…
Sedana Medical AB’s Interim report January-September 2023
Regulatory
All-time-high Q3 sales and further steps towards ex-US profitability
Financial Calendar
| Year-End Report 2023 | 15 February 2024 | 07:00 |
| Annual Report 2023 | 15 April 2024 | 07:00 |
